Patents Assigned to Neuracle Science Co., Ltd.
  • Patent number: 12247070
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: March 11, 2025
    Assignee: NEURACLE SCIENCE CO., LTD.
    Inventors: Bongcheol Kim, Dong Sik Kim, Jae-Keun Lee, Juwon Shim
  • Publication number: 20250067755
    Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
    Type: Application
    Filed: July 18, 2024
    Publication date: February 27, 2025
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Jae Young SEONG, Byung Joo HAM, Min-Hyeok LEE, Nui HA
  • Patent number: 12215338
    Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: February 4, 2025
    Assignees: Neuracle Science Co., Ltd., Neuracle Genetics
    Inventors: Jong-Mook Kim, Dong Sik Kim, Juwon Shim, Soon-gu Kwon
  • Patent number: 12202889
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
    Type: Grant
    Filed: April 18, 2022
    Date of Patent: January 21, 2025
    Assignee: NEURACLE SCIENCE CO., LTD.
    Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
  • Publication number: 20240360209
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
    Type: Application
    Filed: April 1, 2024
    Publication date: October 31, 2024
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Wonkyum KIM, Jeongwon YOON, Junho CHUNG, Junyeong JIN, Eunhwoi YOU
  • Patent number: 12077579
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: September 3, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Patent number: 12072339
    Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 27, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Jae Young Seong, Byung Joo Ham, Min-Hyeok Lee, Nui Ha
  • Publication number: 20240238445
    Abstract: The present disclosure provides mimic molecules that are capable of specifically targeting a FAM19A5 protein, and thereby, inhibiting, reducing, and/or dissociating the interaction between members of the LRRC4 protein family and the FAM19A5 protein. The present disclosure also provides methods for promoting neurite outgrowth, by administering a mimic molecule described herein.
    Type: Application
    Filed: July 8, 2022
    Publication date: July 18, 2024
    Applicant: NEURACLE SCIENCE CO., LTD.
    Inventors: Jae Young SEONG, Youngjoo BYUN, Hoyun KWAK, Sitaek OH, Min-Hyeok LEE, Yongwoo JEONG, Nui HA, Eun-Ho CHO, Suhyun LEE, Sang-Myeong LEE, Yerim LEE, Eun Bee CHO, Jae Keun LEE, Han-Byul KIM, Soon-gu KWON
  • Publication number: 20240182555
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
    Type: Application
    Filed: July 27, 2023
    Publication date: June 6, 2024
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON
  • Publication number: 20240175880
    Abstract: The present disclosure relates to the use of LRRC4 family mimic molecules to determine the expression level of FAM19A5 protein in a subject. In some aspects, such mimic molecules can be used to identify and/or diagnose a subject suffering from or at risk of developing a disease or disorder associated with increased FAM19A5 protein expression. The present disclosure also provides methods of treating subjects identified and/or diagnosed using the methods provided herein.
    Type: Application
    Filed: November 23, 2022
    Publication date: May 30, 2024
    Applicant: NEURACLE SCIENCE CO., LTD.
    Inventors: Jae Young SEONG, Hoyun KWAK, Sitaek OH, Min-Hyeok LEE
  • Publication number: 20240166735
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Application
    Filed: July 11, 2023
    Publication date: May 23, 2024
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Jae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
  • Patent number: 11970532
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 30, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Wonkyum Kim, Jeongwon Yoon, Junho Chung, Junyeong Jin, Eunhwoi You
  • Publication number: 20230357378
    Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
    Type: Application
    Filed: April 17, 2023
    Publication date: November 9, 2023
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON
  • Publication number: 20230348584
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
    Type: Application
    Filed: January 23, 2023
    Publication date: November 2, 2023
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Eun Bee CHO, Dong Sik KIM, Jae-Keun LEE, Soon-gu KWON, Jae Young SEONG, Juwon SHIM, Tae Woo KIM, Shin-hyuk KANG
  • Publication number: 20230287096
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
    Type: Application
    Filed: March 2, 2023
    Publication date: September 14, 2023
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Jae-Keun LEE, Dong Sik KIM, Junho CHUNG, Junyeong JIN
  • Patent number: 11746149
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 5, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Dong Sik Kim, Soon-gu Kwon
  • Patent number: 11739141
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: August 29, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
  • Patent number: 11634484
    Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 25, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Dong Sik Kim, Soon-Gu Kwon
  • Publication number: 20230104540
    Abstract: The present disclosure relates to a method of treating a disease or disorder associated with an abnormality in CNS function. Also provided is a method for diagnosing and/or identifying a subject having an abnormality in CNS function. FAM19A1 antagonists that can be used with the present disclosures are also provided.
    Type: Application
    Filed: March 2, 2021
    Publication date: April 6, 2023
    Applicant: NEURACLE SCIENCE CO., LTD.
    Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON, Nui HA, Jae Young SEONG, Jong Ik HWANG, Hyo Jung YONG, Eun Bee CHO
  • Patent number: 11618783
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: April 4, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim, Junho Chung, Junyeong Jin